Abstract: Hydrogel compositions prepared from amine components and glycidyl ether components are provided which are biocompatible and suitable for use in vivo due, in part, to their excellent stability.

Abstract: The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope 18F comprising a fluorination step for a 2-nitropurine derivative. The present invention comprises a 2-fluoropurine derivative marked with the radioisotope 18F which can be obtained by or during a method according to the invention and its various uses.

Abstract: The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.

Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.

Abstract: Superparamagnetic nanocomposites are provided. In an embodiment, a superparamagnetic nanocomposite comprises a superparamagnetic core comprising a first, soft superparamagnetic ferrite and a superparamagnetic shell comprising a second, soft superparamagnetic ferrite, the shell formed over the core, wherein the first and second soft superparamagnetic ferrites are different compounds and have different magnetocrystalline anisotropies.

Abstract: The pH-responsive ultrasensitive fluorescent nanoprobe is composed of pH-responsive matrix materials and fluorescent organic small molecule dyes. The pH-responsive matrix materials are calcium phosphate, calcium hydroxyphosphate, fluorapatite, calcium carbonate or ZIF series; the fluorescent organic small molecule dyes are positively charged dyes or negatively charged dyes. The preparation method includes: coating a positively charged dye with a negatively charged matrix material; coating a negatively charged dye with a negatively charged matrix material; and coating a negatively charged dye with a positively charged matrix material.

Abstract: Hypoxia occurs when limited oxygen supply impairs physiological functions and is a pathological hallmark of many diseases including cancer and ischemia. Thus, detection of hypoxia can guide treatment planning and serve as a predictor of patient prognosis. Current methods suffer from invasiveness, poor resolution and low specificity. To address these limitations, various hypoxia-responsive probes (HyPs) for photoacoustic imaging are disclosed. The emerging modality converts safe, non-ionizing light to ultrasound waves, enabling acquisition of high-resolution 3D images in deep tissue. The HyPs feature an N-oxide trigger that is reduced in the absence of oxygen by haem proteins such as CYP450 enzymes. Reduction of HyPs produce a spectrally distinct product, facilitating identification via photoacoustic imaging. HyPs exhibit selectivity for hypoxic activation in vitro, in living cells and in multiple disease models in vivo.

Abstract: The present invention relates to: a novel merocyanine-based compound which exhibits a fluorescence signal at a visible light region of at least 380 nm, and which may be used for detecting biomolecules; and a biomolecular labeling dye, kit and contrast agent composition comprising the same.

Abstract: The present invention provides certain compounds, or salts or solvates thereof, which can be used as matrix metalloproteinase-targeted inhibitors or imaging agents.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula: (I) or a pharmaceutically acceptable salt thereof.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.

Abstract: The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

Abstract: Nanoparticles having radially-oriented pores are fabricated from a noble metal. The pores have a specific geometrical shape, such as a circle, triangle, hexagon or other polygon. The nanoparticles are administered to a subject to form a nanoparticle-loaded tumor, which is targeted with a radiation beam as part of a radiotherapeutic treatment. The pores redirect photons of the radiation beam to intensify and enhance the dose received by tumor cells, while concomitantly reducing the dose received by surrounding cells and/or tissues. The nanoparticles may be combined with a radiosensitizing drug or agent, administered together or separately, to form a dose-enhancement composition that further intensifies the received dose of radiation at the target.

Abstract: The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.

Abstract: The present invention pertains to a novel liposome-based contrast agent that is for suppressing absorption in the reticuloendothelial system and for tumor-specific delivery of a radiolabeled substance. More specifically, the present invention pertains to: a liposome contrast agent containing a lipid and a compound of chemical formula 1, which is a radiolabeled substance, the liposome contrast agent being characterized in that the lipid is composed of (a) cholesterol, (b) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and (c) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy(polyethylene glycol)-2000] (DSPE-PEG2000); and a cancer diagnostic composition containing the liposome contrast agent as an active ingredient.

Abstract: In some aspects, the present disclosure provides compounds of the formula: wherein the variables are defined herein. In some aspects, the present disclosure provides methods of preparing imaging agents, compositions thereof, and methods of imaging using said imaging agents or compositions thereof.

Abstract: In one embodiment, the present application discloses compounds that are selective neuroactive agents for the treatment of diseases of the central nervous system (CNS). In one aspect, the neuroactive agents are NCDs of metal chelates, including complexes of iron, copper or zinc.

Abstract: The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.